Cancer Treatment Reviews
Volume 26, Issue 5 , Pages 351-362 , October 2000

A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma

References 

  1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33
  2. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657–1664
  3. Herrington LJ, Weiss NS, Olshan AF. The epidemiology of myeloma. In:  Malpas JS,  Bergsagel DE,  Kyle RA editor. Myeloma. Biology and Management. Oxford: Oxford University Press; 1995;p. 127–168
  4. Kyle RA. ‘Benign’ monoclonal gammopathy—after 20 to 35 years of follow-up. Mayo Clin Proc. 1993;68:26–36
  5. Greipp PR, Kyle RA. Staging, kinetics, and prognosis of multiple myeloma. In:  Wiernik PH,  Canellos GP,  Dutcher JP,  Kyle RA editor. Neoplastic Diseases of the Blood. New York: Churchill Livingstone; 1996;p. 537–559
  6. J Clin Oncol. 1998;16:3832–3842
  7. Kovacsovics T, Delaly A. Intensive treatment strategies in myeloma. Semin Hematol. 1997;34:49–60
  8. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484–489
  9. Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer. 1997;79:1157–1561
  10. Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol. 1997;34:61–66
  11. Barlogie B, Jagannath S, Epstein J. Biology and therapy of multiple myeloma in 1996. Semin Hematol. 1997;34:67–72
  12. Gertz MA, Pineda AA, Chen MG. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci. 1995;309:152–161
  13. Attal M, Harousseau JL, Stoppa AM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97
  14. Fermand JP, Ravaud P, Chevret S. Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): Results of a prospective randomized trial. Blood. 1996;88:685a
  15. Facon T, Mary JY, Harousseau JL. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol. Blood. 1996;88:685a
  16. Shustik C. Interferon in the treatment of multiple myeloma. Cancer Control. 1998;5:226–234
  17. Oken MM, Leong T, Lenhard RE. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer. 1999;86:957–968
  18. Mandelli F, Avvisati G, Amadori S. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990;322:1430–1434
  19. Browman GP, Bergsagel D, Sicheri D. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1995;13:2354–2360
  20. Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. Br J Haematol. 1995;89:561–568
  21. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol. 1994;12:2405–2414
  22. Peest D, Deicher H, Coldewey R. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer. 1995;2:146–151
  23. Ludwig H, Cohen AM, Polliack A. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol. 1995;6:467–476
  24. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763
  25. Fox SB. Tumour angiogenesis and prognosis. Histopathology. 1997;30:294–301
  26. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8
  27. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999;13:469–472
  28. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815–821
  29. Vacca A, Ribatti D, Roncali L. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503–508
  30. Bostwick DG, Wheeler TM, Blute M. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996;48:47–57
  31. Vermeulen PB, Gasparini G, Fox SB. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer. 1996;14:2474–2484
  32. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol. 1995;177:275–283
  33. Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. J Pathol. 1996;179:232–237
  34. Rajkumar SV, Fonseca R, Ansell SM, Witzig TE, Gertz MA, Greipp PR. Computerized image analysis in the assessment of bone marrow angiogenesis in multiple myeloma. Blood. 1998;92:100a
  35. Vacca A, Ribatti D, Presta M. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064–3073
  36. Rajkumar SV, Leong T, Fonseca R. Bone marrow angiogenesis has prognostic value in multiple myeloma. An Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol. 1999;18:19a
  37. Rajkumar SV, Leong T, Roche PC. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6:3111–3116
  38. Munshi N, Wilson CS, Penn J. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies. Blood. 1998;92:98a
  39. Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metas Rev. 1998;17:241–248
  40. Rajkumar SV, Yoon SY, Li CY. Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells. Blood. 1999;94:303b
  41. Fukushima Y, Byers MG, Fiddes JC, Shows TB. The human basic fibroblast growth factor gene (FGFB) is assigned to chromosome 4q25. Cytogenet Cell Genet. 1990;54:159–160
  42. Witzig TE, Kimlinger T, Stenson M, Therneau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymph. 1998;31:167–175
  43. Chesi M, Nardini E, Brents LA. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet. 1997;16:260–264
  44. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999;9:211–220
  45. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203–212
  46. Fiedler W, Graeven U, Ergun S. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–1875
  47. Ito A, Hirota S, Mizuno H. Expression of vascular permeability factor (VPF/VEGF) messenger RNA by plasma cells: possible involvement in the development of edema in chronic inflammation. Pathol Internatl. 1995;45:715–720
  48. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728–733
  49. Dankbar B, Padro T, Leo R. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630–2636
  50. Rajkumar SV, Yoon SY, Li CY. Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells. Blood. 1999;94:303b
  51. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358
  52. Argiles JM, Carbo N, Lopez-Soriano FJ. Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s?. Med Hypoth. 1998;50:313–318
  53. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Med. 1999;5:582–585
  54. Iyer CG, Languillon J, Ramanujam K. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull WHO. 1971;45:719–732
  55. Jacobson JM, Greenspan JS, Spritzler J. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1487–1493
  56. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996;10:1501–1507
  57. Hamuryudan V, Mat C, Saip S. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443–450
  58. Parker PM, Chao N, Nademanee A. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86:3604–3609
  59. Kulkarni S, Powles R, Mehta J. Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. Blood. 1997;90:376a
  60. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675–1680
  61. Stirling DI. Pharmacology of thalidomide. Semin Hematol. 2000;37:5–14
  62. Turk BE, Jiang H, Liu JO. Binding of thalidomide to alphal-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA. 1996;93:7552–7556
  63. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885–1892
  64. McHugh SM, Rifkin IR, Deighton J. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99:160–167
  65. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31:213–221
  66. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–4085
  67. Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971–978
  68. Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol. 1998;26:217–221
  69. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anti Cancer Drugs. 1996;7:339–343
  70. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol. 1998;55:1827–1834
  71. O’Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 1996;2:689–692
  72. O’Reilly MS, Boehm T, Shing Y. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285
  73. O’Reilly MS, Holmgren L, Shing Y. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315–328
  74. Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–407
  75. Singhal S, Mehta J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571
  76. Rajkumar SV, Fonseca R, Dispenzieri A. Thalidomide in the treatment of relapsed and refractory myeloma. Blood. 1999;94:316a
  77. Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood. 1999;94:604a
  78. Durie BGM, Stepan DE. Efficacy of low dose thalidomide (T) in multiple myeloma. Blood. 1999;94:316a
  79. Juliusson G, Celsing F, Turesson I, Adriansson M, Malm C. Thalidomide frequently induces good partial remission and best response ever in patients with advanced multiple myeloma and prior high dose melphalan and autotransplant. Blood. 1999;94:124a
  80. Kneller A, Raanani P, Hardan I. Therapy with thalidomide in refractory multiple myeloma- the revival of an old drug. Br J Haematol. 2000;108:391–393
  81. Shima Y, Treon SP, Yoshizaki K. Clinical and biological activity of thalidomide (THAL) in multiple myeloma (MM). Blood. 1999;94:125a
  82. Neben K, Hawighorst H, Moehler TM. Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. Blood. 1999;94:124a
  83. Sabir T, Raza S, Anderson L, Jagannath S. Thalidomide is effective in the treatment of recurrent refractory multiple myeloma (MM). Blood. 1999;94:125a
  84. Cheng D, Kini AR, Rodriguez J, Burt R, Peterson LC, Traynor AE. Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. Blood. 1999;94:315a
  85. Schiller G, Vesico R, Berenson J. Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. Blood. 1999;94:317a
  86. Barlogie B, Desikan R, Munshi N. Single course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM). Blood. 1998;92:273b
  87. Munshi N, Desikan R, Zangari M. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma. Blood. 1999;94:123a
  88. Fine HA, Figg WD, Jaeckle K. A phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708–715
  89. Figg WD, Bergan R, Brawley O. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol. 1997;16:333a
  90. Klohs WD, Hamby JM. Antiangiogenic agents. Curr Opin Biotechnol. 1999;10:544–549
  91. Twardowski P, Gradishar WJ. Clinical trials of antiangiogenic agents. Curr Opin Oncol. 1997;9:584–589
  92. Fox SB, Harris AL. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest New Drugs. 1997;15:15–28
  93. Ryan AM, Eppler DB, Hagler KE. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol. 1999;27:78–86
  94. Witte L, Hicklin DJ, Zhu Z. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metast Rev. 1998;17:155–161
  95. Prewett M, Huber J, Li Y. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209–5218
  96. Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica. 1999;84:643–650
  97. Cirri L, Donnini S, Morbidelli L, Chiarugi P, Ziche M, Ledda F. Endostatin: a promising drug for antiangiogenic therapy. Internatl J Biol Markers. 1999;14:263–267
  98. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res. 1998;58:2269–2277
  99. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann NY Acad Sci. 1999;889:84–86

PII: S0305-7372(00)90188-9

doi: 10.1053/ctrv.2000.0188

Cancer Treatment Reviews
Volume 26, Issue 5 , Pages 351-362 , October 2000

Article Tools